| P/E (FY) | — | Sales (TTM) | $453.3M |
| Earnings (TTM) | -$178.1M | ROE | −22.56% |
| Net Margin | −38.15% | ROIC | −415.92% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 28.86% |
| Market Cap | $20.39B | Trading Days | 2219 |
| 52W High | 41.20 |
| 52W Low | 15.96 |
| % Off High | −54.81% |
| YTD | 5.56% | 1Y | −51.87% |
| 3Y | −40.87% | 5Y | −86.95% |
| Since incept. (ann.) | −4.48% |
Zejula 41% · Vyvgart Vyvgart Hytrulo 21% · Nuzyra 13% · Optune 11% · …
| Ann. Volatility (1Y) | 51.44% | Ann. Volatility (3Y) | 60.27% |
| Sharpe (1Y) | −1.20 | Sharpe (3Y) | 0.03 |
| Max Drawdown (1Y) | −59.76% | Max Drawdown (3Y) | −62.12% |
| Beta (3Y, vs SPY) | 0.23 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| VTRS | Viatris Inc | $20.80B | — |
| UTHR | UNITED THERAPEUTICS Corp | $22.23B | 18.8 |
| INSM | INSMED Inc | $22.57B | — |
| ROIV | Roivant Sciences Ltd. | $24.34B | — |
| BBIO | BridgeBio Pharma, Inc. | $16.76B | — |
| JAZZ | Jazz Pharmaceuticals plc | $16.12B | — |
| QNRX | Quoin Pharmaceuticals, Ltd. | $14.09B | — |
| ZTS | Zoetis Inc. | $32.49B | 12.9 |
| ELAN | Elanco Animal Health Inc | $12.75B | — |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | $12.42B | — |
| RPRX | Royalty Pharma plc | $33.85B | 33.7 |
| ARROWHEAD PHARMACEUTICALS, INC. |
| $12.08B |
| — |
